Points well taken. Let's see how things unfold at ResMed over...

First 22 Last

Share
Profile

Follow
nickdany123

292 Posts.

90

27/01/19

11:41

Post #: 37236914
Share

Originally posted by Msim878: ↑

Granted it was priced to perfection coming in to the results. Software as a segment is still a very small part of RMD's total revenue base but it's something that management are clearly favouring and leaning towards as a future driver of growth for the business.

Ok so there are the facts:

-The core devices business was sluggish, growing just 3% on the prior corresponding period on a constant-currency basis.
-In U.S., Canada, and Latin America devices, sales growth of 7% was offset by revenue declining in the rest of world markets, with France and Japan particularly challenged following digital health upgrade systems in those countries.
-Reality is RMD should expand the devices business at a high-single-digit compound annual growth rate over the medium term as it increases its share of an unpenetrated and growing market.
-The masks business increased revenue 10% on the prior corresponding period on a constant-currency basis, outpacing the lower-margin devices business.
-This favourable shift in product mix, along with manufacturing efficiencies, allowed ResMed to enjoy a 70-basis-point expansion in gross margin from 58.2% in the first quarter to 58.9% in the second quarter. - Market has missed this completely because its too preoccupied with revenue.

You say that the CEO and CFO were looking for words and dodging questions, here's a direct quote from the CEO in a post results interview.

“I don’t get too excited about it being up in one day or too upset about it being down in one day. I’m really focused on that one-, three- and five-year picture.“I feel good about the five-year picture and it is an opportunity now for people to buy in and focus on that five year picture.”

A big reason why professional investors have placed confidence and backed this company has been management and how astute they have been in terms of running the company.

Again with respect, those sales by insiders are hardly material and while I understand what your trying to say I don't think there's anything sinister looking at those numbers...have seen so much worse.

Expand

Points well taken. Let's see how things unfold at ResMed over the next 12 - 18 months. Good luck to all holders!

RMD Price at posting: $14.47 Sentiment: None Disclosure: Not Held
4 Upvote

0 Great analysis

Reply

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

SIG

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

HotCopper Highlights: Your most watched stocks for Week 47, 2024

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

DUI

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

LPE

Sales growth pushes Lovisa's fortunes (and shares) upwards

PYC

Scientific conference spotlights PYC's work on blindness disease treatment

There are more pages in this discussion • 130 more messages in this thread...

First 22 Last

Add RMD (ASX) to my watchlist

(20min delay)
Last $37.28		Change 0.200(0.54%)		Mkt cap ! $22.38B

Open	High	Low	Value	Volume
$37.50	$37.55	$37.15	$17.93M	480.5K

Buyers (Bids)

No.	Vol.	Price($)
1	3363	$37.27

Sellers (Offers)

Price($)	Vol.	No.
$37.30	1001	2

View Market Depth

No.	Vol.	Price($)
2	13767	14.400
2	17668	14.390
3	20967	14.380
2	14124	14.370
4	21382	14.360

Price($)	Vol.	No.
14.430	22863	3
14.440	27216	4
14.450	46627	8
14.460	34563	7
14.470	22668	7

Last trade - 16.10pm 22/11/2024 (20 minute delay)

RMD (ASX) Chart

Points well taken. Let's see how things unfold at ResMed over...

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

HotCopper Highlights: Your most watched stocks for Week 47, 2024

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL

Panic, paranoia, and gangland politics: HotCopper users react to Dubber's missing $26M

Sales growth pushes Lovisa's fortunes (and shares) upwards

Scientific conference spotlights PYC's work on blindness disease treatment

Buyers (Bids)

Sellers (Offers)